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ABSTRACT
Background/aims: Tumour-necrosis-factor-related
apoptosis-inducing ligand (TRAIL) plays a role in the
development of allergic asthma. The study aimed to
determine whether TRAIL also participates in the
development of experimental allergic conjunctivitis (EC),
another allergic disease model.
Methods: EC was induced in BALB/c mice by active
immunisation with ragweed (RW) followed by RW
challenge. To investigate whether TRAIL in the conjunctiva
plays a role in the development of EC, conjunctival TRAIL
expression in EC-developing mice was evaluated by
immunohistochemistry. Additionally, the effect of sub-
conjunctival injection of recombinant TRAIL on conjuncti-
val inflammation was examined. To investigate whether
TRAIL expressed in systemic immunocompetent cells
plays a role in the development of EC, anti-TRAIL blocking
Ab or anti-TRAIL receptor agonistic Ab was intraperito-
neally injected into EC-developing mice, and conjunctival
eosinophil infiltration was evaluated.
Results: Conjunctival TRAIL expression was not
increased by EC induction. Moreover, subconjunctival
injection of TRAIL protein in naı¨ve mice did not induce
conjunctival inflammation. Thus, TRAIL in the conjunctiva
is less likely to participate in the development of EC.
Systemic treatment with anti-TRAIL blocking Ab in EC-
developing mice did not affect the severity of EC.
However, systemic treatment during the induction phase
of EC with an agonistic Ab for the TRAIL receptor
significantly augmented the severity of EC and increased
Ag-recall splenocyte IFN-c production in vitro.
Conclusions: These results indicate that TRAIL receptor-
expressing cells in lymphoid organ participate in the
development of EC.
Tumour necrosis factor (TNF)-related apoptosis-
inducing ligand (TRAIL) is a member of the TNF
superfamily of cytokines.1 2 The physiological
functions of TRAIL are not yet fully understood,
but mouse gene knock-out studies indicate that
this agent has an important role in anti-tumour
surveillance by immune cells, mediates thymocyte
apoptosis and is important in the induction of
autoimmune diseases.3 In humans, TRAIL binds to
two death-inducing receptors, DR4/TRAIL-R1 and
DR5/TRAIL-R2/KILLER. TRAIL has also been
shown to bind three decoy receptors, DcR1/
TRID/TRAIL-R3, DcR2/TRAIL-R4 and a soluble
receptor osteoprotegerin (OPG) that was originally
identified as a receptor for OPGL/RANKL.4 In the
mouse, only one death-inducing receptor has been
described that shares homology to human TRAIL-
R2 (mouse DR5).4 TRAIL receptors are expressed in
many different types of cells, including astrocytes
and hepatocyotes in addition to immune cells.4
It has been reported that TRAIL participates in
the regulation of different types of immune
responses and inflammation.5 With regard to
allergic diseases, patients with asthma show a
significant increase in the levels of TRAIL in
bronchoalveolar lavage fluid after allergen chal-
lenge.6 It was also demonstrated recently that
TRAIL is abundantly expressed in the airway
epithelium of mice developing experimental
asthma.7 Furthermore, studies using TRAIL-defi-
cient mice and short interfering RNA targeting
TRAIL revealed that inhibition of TRAIL signalling
impairs the production of CCL20 and the homing
of myeloid dendritic cells and CCR6- and CD4-
expressing T cells to the airways.7 Thus, TRAIL
appears to play a pivotal role in the development of
asthma. However, to date, the roles TRAIL plays in
other types of allergic diseases have not been
investigated.
Allergic conjunctivitis (AC) is an allergic eye
disease that ranges from mild forms such as
seasonal AC to severe forms such as vernal
keratoconjunctivitis (VKC).8 In VKC patients,
eosinophils infiltrating into the conjunctiva affect
the adjunct tissue cornea, sometimes leading to
vision loss.9 Our group has investigated the
mechanism that leads to VKC by inducing experi-
mental allergic conjunctivitis (EC) in rats10–12 and
mice.13–15 We found that Ag-specific T cells,
especially Th2 cells, play a crucial role in the
infiltration of eosinophils into the conjunctiva
during the development of EC.
Here, we sought to investigate whether TRAIL
participates in the development of the allergic eye
disease model EC.
MATERIALS AND METHODS
Mice
Inbred wild-type (WT) BALB/c mice were pur-
chased from Japan SLC, Hamamatsu, Shizuoka,
Japan. The mice were kept in specific pathogen-
free conditions at the animal facility of Kochi
Medical School, and age- and gender-matched mice
were used when they were 6–12 weeks old. All
research adhered to the Association for Research in
Vision and Ophthalmology Statement for the Use
of Animals in Ophthalmic and Vision Research.
Reagents
Short ragweed pollen (RW) was purchased from
Polysciences (Warrington, PA). RW extract was
obtained from LSL Co. Ltd (Tokyo). Aluminium
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hydroxide (alum) was purchased from Sigma (St Louis, MO).
Generation and characterisation of the anti-mouse TRAIL
blocking Ab (N2B2, rat IgG)16 and the anti-mouse TRAIL
receptor (DR5) agonistic Ab (MD5-1, hamuster IgG)17 have been
described in our previous papers. These Abs for in vivo
treatments were purified from ascites by using protein G
columns. The Ab preparations contained less than 100 pg/ml
endotoxin. Normal rat IgG (nrIgG) and normal hamster IgG
(nhIgG) were obtained from MP Biomedicals, Aurora, OH.
EC induction by active immunisation and treatment with Abs
RW adsorbed on alum was injected into the left hind-footpad
and the tail base. Fifty microlitres of the emulsion (50 mg of RW
and 675 mg of alum) was injected into each site. The mice were
injected intraperitoneally with 200 mg of purified anti-TRAIL,
anti-DR5 Ab, or control rat or hamster IgG (n = 10 per group)
on days 0, 2, 4, 6 and 8 after immunisation (induction phase). In
a separate experiment, the actively immunised mice (n = 10 per
group) were injected intraperitoneally with 200 mg of Ab only
once 2 h before the RW challenge (effector phase). Ten days
after active immunisation, the eyes of the immunised mice were
challenged with RW in PBS (2 mg in 10 ml per eye). Twenty-
four hours later, the eyes and spleens were harvested for
histological analysis and cytokine assays or flow cytometric
anlaysis, respectively.
Induction of EC by adoptive transfer of in vitro-stimulated and
Ab-treated RW-primed splenocytes
Naı¨ve BALB/c mice were immunised with RW in their left hind-
footpad and tail base, and were not treated with any Abs. Ten
days later, their splenocytes were prepared and cultured with
5 mg/ml RW extract as described previously13 15 in the presence
of 10 mg/ml anti-DR5 Ab or nhIgG (n = 5 per group). After
incubation for 72 h at 37uC in a humidified atmosphere with
5% CO2, 26107 splenocytes were intraperitoneally injected into
naı¨ve mice. Four days after the splenocyte transfer, the eyes of
the recipient mice were challenged with RW in PBS (2 mg in
10 ml per eye). Twenty-four hours later, the eyes were harvested
for histological analysis.
Subconjunctival injection of recombinant mouse TRAIL
Recombinant mouse (rm)TRAIL (Biomol, Plymouth Meeting,
PA; 1.56 mg in 3 ml of 0.1 mM DTT/PBS) was injected into the
subconjunctival space of naı¨ve mice (n = 5). As a control, 3 ml of
0.1 mM DTT/PBS (vehicle) was injected (n = 5). Twenty-four
hours after injection, the conjunctivas were harvested for
histological analysis.
Histological analysis
The eyes including the conjunctivas were harvested and fixed in
10% buffered formalin. Vertical 2 mm thick sections were cut
and stained with Giemsa. Infiltrating eosinophils in the lamina
propria mucosae of the tarsal and bulbar conjunctivas through-
out each section were counted by two blinded observers. The
sections counted were those of the central portion of the eye,
which included the pupil and optic nerve head. The data are
presented as averages (SEM) of all the mice examined.
Immunohistochemistry
Conjunctivas from actively immunised BALB/c mice were
harvested 24 h after RW challenge. In addition, conjunctivas
from naı¨ve BALB/c mice were collected. The conjunctivas
were embedded in OCT compound (VWR, Suwanee, GA) and
snap-frozen in liquid nitrogen. Vertical 4 mm sections were
prepared and fixed in methanol. Endogenous peroxidase
activity was inhibited by incubation with 0.1% NaN3 and
0.3% H2O2 in distilled water for 10 min at room temperature.
The samples were exposed to the anti-TRAIL Ab or anti-DR5
Ab for 30 min and then to appropriate biotinylated secondary
Ab for another 30 min. Ab binding was revealed by using an
Avidin–Biotin-Complex kit (Vector Laboratories, Burlingame,
CA) followed by development with 3,39-diaminobenzidine
tetrahydrochloride (Sigma).
Measurement of cytokines in the culture supernatants
RBC-depleted splenocytes (107 cells/ml) were cultured for 48 h
with RW extract (25 mg/ml) in 96-well flat-bottom plates in a
final volume of 0.2 ml RPMI 1640 medium supplemented with
10% FCS and 2-ME. The levels of IL-4, IL-5, IL-12 and IFN-c
that were produced were measured by using Luminex100
(Luminex, Austin, TX) and the Bio-Plex Cytokine Assay Panel
(Bio-Rad Laboratories, Hercules, CA) according to the manu-
facturers’ instructions.
Flow-cytometric analysis
RBC-depleted splenocytes from naı¨ve mice or actively immu-
nised and nrIgG-treated mice as described above were subjected
to flow cytometric analysis to detect TRAIL- or DR5-expressing
cells. To examine the effect of anti-DR5 Ab on splenocytes,
RBC-depleted splenocytes from naı¨ve mice were cultured as
described above (following the method for splenocyte transfer)
in the presence of either nhIgG or anti-DR5 Ab (10 mg/ml).
Twenty-four hours later, the splenocytes were harvested and
initially stained with biotin-labelled anti-CD4 Ab or anti-CD8
Ab followed by streptavidin-PE staining. Then, these cells were
stained with annexin V-fluorescein isothiocyanate according to
the manufacturer’s recommendations (BioVision, Mountain
View, CA). Dead cells were excluded by 7-amino-actinomycin
D (7-AAD). The cells were then analysed on a FACScan (Becton
Dickinson, Mountain View, CA), and the data were acquired
and analysed by using CellQuest software.
Statistical analysis
Differences between the Ab-treated and control IgG-treated
mice in terms of their cytokine production and infiltrating
eosinophil numbers were tested for significance using the
Student t test. p Values less than 0.05 were considered
significant.
RESULTS
TRAIL is not induced in the conjunctiva by the induction of EC
A previous report showed that TRAIL was induced in the
airway epithelium by the induction of experimental asthma. To
examine whether this is also the case in EC, an immunohisto-
chemical analysis was performed to detect TRAIL expression in
the conjunctiva. TRAIL expression was barely detected in either
naı¨ve or EC-developing conjunctivas (fig 1A). Similarly, expres-
sion of DR5 was hardly detectable in the conjunctiva from
either naı¨ve or EC-developing mice (data not shown).
Subconjunctival injection of rmTRAIL does not induce
conjunctival inflammation
A previous report demonstrated that intratracheal administra-
tion of rmTRAIL in naı¨ve animals induced airway hyperrespon-
siveness and inflammation.7 We thus asked whether injecting
rmTRAIL into the subconjunctival space of naı¨ve mice would
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induce conjunctival inflammation. However, there was no
difference between the rmTRAIL-injected and vehicle-injected
groups in terms of conjunctival eosinophil infiltration when it
was evaluated 24 h later (fig 1B). T cells, but not B cells and
neutrophils, also infiltrated into the conjunctiva (data not
shown).
Systemic blockade of TRAIL does not affect EC or RW-recall
immune responses
The above findings suggest that TRAIL in the conjunctiva is less
likely to be involved in the development of EC. Therefore, we
next investigated whether systemic TRAIL participates in the
development of EC. For this, anti-TRAIL blocking Ab was
injected intraperitoneally into mice that had been immunised
with RW and were then challenged with RW in eye-drops. Anti-
TRAIL Ab was either injected during the induction phase (five
times every other day from the day of immunisation) or during
the effector phase (2 h prior to RW challenge). Anti-TRAIL Ab
treatment during the induction and effector phases slightly
suppressed (fig 2A) and elevated (fig 2C) the severity of EC,
respectively, but these changes did not achieve statistical
significance. The RW-recall cytokine production of splenocytes
from these mice did not vary, regardless of when, during the
disease process, the mice had been treated with anti-TRAIL Ab
(fig 2B,D). Importantly, TRAIL-expressing cells constituted less
than 1% of the whole splenocyte population and their TRAIL
expression levels were minute (percentage positive: 0.14 (0.00)
in naı¨ve mice and 0.60 (0.04) in nrIgG-treated actively
immunised group).
Agonistic stimulation of TRAIL receptor affects EC and immune
responses
To investigate whether forced stimulation of systemic TRAIL
receptor affects the severity of EC, RW-immunised mice were
injected intraperitoneally with anti-DR5 Ab, an agonistic Ab for
mouse TRAIL receptor, during the induction phase (5 times
every other day from the day of immunisation) or the effector
phase (2 h prior to RW challenge). Anti-DR5 Ab treatment
during the induction phase significantly elevated the severity of
EC, as indicated by conjunctival eosinophil numbers (fig 3A).
Anti-DR5 Ab treatment also increased conjunctival eosinophil
infiltration when delivered during the effector phase (fig 3C),
although this difference did not reach statistical significance.
Anti-DR5 Ab treatment during the induction phase also
significantly upregulated RW-recall IFN-c production, while
the other cytokines tested were not affected (fig 3B). In
contrast, effector phase treatment with anti-DR5 Ab did not
affect the cytokine production (fig 3D). Similar to the data of
TRAIL, TRAIL receptor expression levels in splenocytes were
minute (percentage positive: 0.21 (0.02) in naı¨ve mice 0.67
(0.09) in nhIgG-treated actively immunised group).
Stimulation of RW-primed splenocytes with anti-DR5 Ab
increased IL-5 production and EC-inducing capability but
suppressed IFN-c production
Next, we investigated how in vitro treatment with anti-DR5 Ab
affects RW-primed splenocyte responses. RW-primed spleno-
cytes that were stimulated with RW extract together with anti-
DR5 Ab produced significantly higher amounts of IL-5 and
significantly lower amounts of IFN-c than those that were
cultured with the control nhIgG Ab (fig 4A). Furthermore, the
adoptive transfer into naı¨ve mice of RW-primed splenoctyes
stimulated in vitro with RW-extract and anti-DR5 Ab, followed
by RW challenge 4 days later, induced significantly more severe
EC than adoptive transfer of the nhIgG-treated splenocytes
(fig 4B).
Stimulation of naı¨ve splenocytes with anti-DR5 Ab increased
apoptotic cells
Finally, we investigated whether anti-DR5 Ab induces apoptosis
of splenocytes. Naı¨ve splenocytes were cultured for 24 h in the
presence of either anti-DR5 Ab or nhIgG. These splenocytes
were subjected to flow-cytometric analysis to determine
annexin V-positive cells. Most of splenocytes were 7-AAD-
negative. In both CD4+ and CD8+ T cell compartments, annexin
V-positive cells apparently increased in the presence of anti-DR5
Ab compared with nhIgG (fig 5).
DISCUSSION
While a previous report has shown that TRAIL is induced in
airway epithelium by the induction of experimental asthma,7
the induction of EC did not induce TRAIL in the conjunctiva. It
Figure 1 Roles of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) in the conjunctiva. (A) Expression of TRAIL in the conjunctiva.
Conjunctivas from naı¨ve (a) and EC-developing (b) mice were harvested to evaluate TRAIL expression by immunohistochemical analysis. Minute
amounts of TRAIL protein were detected in the conjunctival epithelial layers, but there was no obvious difference between naı¨ve and EC-developing
mice. *Conjunctival epithelium. Bar = 100 mm. One representative of three samples is shown. (B) Effects of subconjunctival injection of recombinant
mouse TRAIL (rmTRAIL). rmTRAIL or vehicle was injected into the subconjunctival space of naı¨ve BALB/c mice. Twenty-four hours later, the
conjunctivas were harvested for histological analysis to determine conjunctival eosinophil numbers. A significant difference between the two groups
was not observed.
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should be noted that the Ab we used for immunohistochemical
analysis was the same as that used in the previous report.7
Moreover, while it was reported that the intratracheal admin-
istration of rmTRAIL in naı¨ve animals induces pathognomic
features of asthma,7 significant conjunctival inflammation was
not observed after subconjunctival injection of rmTRAIL. These
observations together suggest that it is less likely that TRAIL in
the conjunctiva plays a critical role in the development of EC.
We next investigated whether systemic TRAIL participates in
the development of EC. Blockade of TRAIL during the induction
or effector phase did not affect the severity of EC. We also found
by flow-cytometric analysis that TRAIL expression levels were
minute. This may be why treatment with the blocking anti-
TRAIL Ab did not significantly affect the severity of EC and
splenocyte cytokine production. However, agonistic stimulation
of TRAIL receptor by anti-DR5 Ab during the induction phase
significantly increased the severity of EC and splenocyte IFN-c
production, although TRAIL receptor expression in splenocytes
was at a similar level to that of TRAIL. Thus, it appears that
TRAIL receptor-expressing cells affect the severity of EC.
Indeed, treatment of splenocytes with anti-DR5 Ab in vitro
apparently increased apoptotic cells.
A notable finding was that in vitro Ag-recall splenocyte IFN-c
production was upregulated by in vivo treatment with
Figure 2 Effects of treatment with a
blocking anti-TRAIL blocking Ab on the
severity of experimental allergic
conjunctivitis (EC) and splenocyte
cytokine production. EC was induced in
BALB/c mice by active immunisation with
ragweed (RW) followed by RW challenge.
Twenty-four hours after RW challenge,
the conjunctivas and spleens were
harvested for histological analysis to
determine conjunctival eosinophil
numbers (A, C) and Ag-recall splenocyte
cytokine production (B, D), respectively.
The blocking anti-TRAIL Ab or control
nrIgG was injected intraperitoneally
during the induction phase (A, B) or the
effector phase (C, D). The anti-TRAIL Ab-
and nrIgG-treated groups did not differ
significantly in conjunctival eosinophil
numbers (A, C) and splenocyte cytokine
production (B, D), regardless of when in
the disease process they were treated. In
(A), conjunctival eosinophil numbers in
naı¨ve and RW-challenged BALB/c mice
were presented as a control.
Figure 3 Effects of agonistic anti-DR5
Ab treatment on the severity of
experimental allergic conjunctivitis (EC)
and splenocyte cytokine production. EC
was induced in BALB/c mice by active
immunisation with ragweed (RW)
followed by RW challenge. Twenty-four
hours after RW challenge, the
conjunctivas and spleens were harvested
for histological analysis to determine
conjunctival eosinophil numbers (A, C)
and Ag-recall splenocyte cytokine
production (B, D), respectively. Anti-DR5
agonistic Ab or control nhIgG was
injected intraperitoneally during the
induction phase (A, B) or the effector
phase (C, D). When the treatment was
conducted during the induction phase,
conjunctival eosinophil numbers (A) and
splenocyte IFN-c production (B) were
significantly higher in the anti-DR5 Ab-
treated group than the nhIgG-treated
group. *p,0.05. No significant difference
between the two groups was noted when
the treatment was conducted during the
effector phase (C, D).
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anti-DR5 Ab. With regard to TRAIL expression in T cells, it has
been reported that the activation-induced expression of TRAIL
was exclusively observed in Th2 clones and primary helper T
cells that have differentiated under Th2 conditions.18 It has also
been reported that Th2 cells were more resistant to TRAIL-
induced apoptosis than Th1 cells.18 However, roles TRAIL
receptor plays in Th1/Th2 balance have not been demonstrated.
Stimulation of TRAIL receptor of splenocytes in vitro with anti-
DR5 Ab upregulated IL-5 production but suppressed IFN-c
production. In contrast, the stimulation of TRAIL receptor by
systemic in vivo treatment with anti-DR5 Ab increased
splenocyte IFN-c production. The reason for this discrepancy
is unclear at this point. TRAIL expression is not only restricted
to T cells, as it is also observed in eosinophils19 and some mouse
liver natural killer cells.20 Additionally, it was reported that
treatment with anti-DR5 Ab recruits Fc receptor–expressing
innate immune cells and exhibits anti-tumour effects against
TRAIL-sensitive tumour cells in vivo.17 It is possible that the
effects of agonistic stimulation of TRAIL receptor by intraper-
itoneal injection of anti-DR5 Ab affected innate immune cells as
well as T cells, thereby elevating splenocyte IFN-c production.
How did the upregulated IFN-c production induced by anti-
DR5 Ab treatment in vivo increase the severity of EC? We have
previously shown that endogenous IFN-c promotes the devel-
opment of EC in the BALB/c background but not in the C57BL/
6 background.15 Furthermore, it was also demonstrated that
IFN-c participated in the development of allergic conjunctivitis
during the effector phase in BALB/c mice.21 The latter report
also indicated that IFN-c induced vascular endothelial adhesion
molecule (VCAM)-1 expression in the conjunctival vasculature,
thus inducing infiltration of inflammatory cells into the
conjunctiva.21 These facts are in good agreement with our data
showing that anti-DR5 Ab treatment in vivo increased IFN-c
production and augmented the severity of EC in BALB/c mice.
In contrast, we have also previously demonstrated that
stimulation of Ag-specific T cells in the presence of excessive
IL-4 and IFN-c significantly upregulated and attenuated the EC-
inducing capability (conjunctival eosinophil infiltration) of
these T cells, respectively.22 This is also in good agreement with
the data that anti-DR5 Ab treatment in vitro significantly
attenuated IFN-c production but significantly upregulated
EC-inducing capability.
Endogenous TRAIL is less likely to participate in the
development of EC but forced stimulation of TRAIL receptor
by anti-DR5 Ab significantly augmented the severity of EC. As
mentioned in the Introduction, the ligand of DR5 is TRAIL
alone; however, the ligand of TRAIL is not restricted to DR5 but
also includes decoy receptors. Therefore, the effect of treatment
with anti-DR5 Ab is different from that of endogenous TRAIL
which also affects decoy receptors. It may be possible that the
distribution and abundance of each TRAIL receptor are different
Figure 4 Effects of in vitro treatment with agonistic anti-DR5 Ab on Ag-recall splenocyte responses. BALB/c mice were immunised with ragweed
(RW) in alum. Ten days later, their spleens were harvested, and the splenocytes were stimulated with RW extract in vitro together with anti-DR5 Ab or
nhIgG. Forty-eight hours later, culture supernatants were collected for cytokine assays (A). After 3 days of culture, the stimulated splenocytes were
collected and transferred into naı¨ve BALB/c mice by intraperitoneal injection. Four days later, the recipient mice were challenged with RW in eye-drops,
and 24 h later, the conjunctivas were harvested for histological analysis to determine conjunctival eosinophil numbers (B). Significantly higher amounts
of IL-5 and significantly lower amounts of IFN-c were produced by splenocytes treated in vitro with anti-DR5 Ab compared with the control nhIgG Ab
(A). Adoptive transfer of splenoctyes treated in vitro with anti-DR5 Ab induced significantly more severe experimental allergic conjunctivitis than those
with nhIgG (B). **p,0.01, *p,0.05.
Figure 5 Effects of in vitro treatment with agonistic anti-DR5 Ab on
apoptosis of splenocytes. Splenocytes were harvested from naı¨ve BALB/
c mice were stimulated in vitro with anti-DR5 Ab or nhIgG. Twenty-four
hours later, these splenocytes were subjected to flow-cytometric
analysis to determine the frequencies of annexin V-positive and 7-amino-
actinomycin D (7-AAD)-negative cells in CD4+ and CD8+ T cell
compartments. Most of the splenocytes were negative for 7-AAD. One
representative histogram, based on the data, is shown. Grey line, anti-
DR5 Ab treated splenocytes; black line, nhIgG treated splenocytes; FITC,
fluorescein isothiocyanate.
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between the airways and conjunctiva. This may be one reason
why TRAIL plays a role in the development of experimental
airway inflammation, but not in EC.
In conclusion, TRAIL is less likely to play a significant role in the
development of EC, whereas TRAIL receptor expressing cells in
lymphoidorganparticipate inthedevelopmentofEC.Futurestudies
on TRAIL receptor expression and stimulation in draining lymph
nodes may shed more light on the role of these receptors in EC.
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